
Pancreatic cancer has one of the most suppressive tumor microenvironments in oncology. But two pancreatic cancer results dropped today. Both matter. 1. BioNTech mRNA neoantigen vaccine: nearly all responders still alive at 6 years. 98% of induced T cells were de novo — the immune system learned to see a cancer it had always been blind to. 2. Daraxonrasib: 47% ORR, 92% disease control as first-line monotherapy. KRAS G12D, undruggable for 40 years, finally has a drug. Different mechanisms. Same disease. Both working. <13% of patients survive 5 years. That number is about to change. great day for science! 🔥





















